In Brief: Masimo/Ivy Biomedical
This article was originally published in The Gray Sheet
Masimo/Ivy Biomedical: Enter licensing agreement to allow integration of Masimo's SET signal extraction technology into Ivy's current and future pulse oximeter patient monitors, including its 405T portable multi-function monitor, 405D bedside monitor, and the soon-to-be-launched model 2000 stand-alone monitor. The SET is a pulse oximetry signal processing and sensor platform that allows measurement of weak physiological signals even in the presence of high levels of interfering signals or motion artifact, Masimo claims...
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.